Immunic, Inc. (NASDAQ:IMUX) Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC lessened its stake in shares of Immunic, Inc. (NASDAQ:IMUX) by 27.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,099,278 shares of the company’s stock after selling 1,974,566 shares during the quarter. Janus Henderson Group PLC owned about 0.06% of Immunic worth $8,439,000 at the end of the most recent quarter.

Separately, Vanguard Group Inc. raised its position in Immunic by 100.7% during the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after buying an additional 1,703,047 shares during the last quarter. Institutional investors and hedge funds own 51.82% of the company’s stock.

Insider Buying and Selling

In other Immunic news, Director Richard Alan Rudick acquired 87,300 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were purchased at an average cost of $1.15 per share, with a total value of $100,395.00. Following the purchase, the director now owns 87,300 shares in the company, valued at approximately $100,395. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 3.00% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on IMUX shares. Leerink Partners reaffirmed an “outperform” rating and issued a $5.00 target price on shares of Immunic in a report on Monday, September 9th. HC Wainwright assumed coverage on Immunic in a report on Monday, November 25th. They issued a “buy” rating and a $10.00 price objective on the stock. B. Riley initiated coverage on Immunic in a research report on Tuesday, August 27th. They set a “buy” rating and a $6.00 target price on the stock. StockNews.com cut Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Finally, EF Hutton Acquisition Co. I raised Immunic to a “strong-buy” rating in a report on Monday, September 16th. One analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $11.80.

Immunic Trading Up 4.9 %

IMUX stock opened at $1.28 on Monday. The firm has a 50 day moving average of $1.32 and a 200-day moving average of $1.34. The company has a market cap of $115.30 million, a price-to-earnings ratio of -1.04 and a beta of 1.89. Immunic, Inc. has a 12-month low of $0.97 and a 12-month high of $2.11.

Immunic Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.